Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Garderet, L; Iacobelli, S; Moreau, P; Dib, M; Lafon, I; Niederwieser, D; Masszi, T; Fontan, J; Michallet, M; Gratwohl, A; Milone, G; Doyen, C; Pegourie, B; Hajek, R; Casassus, P; Kolb, B; Chaleteix, C; Hertenstein, B; Onida, F; Ludwig, H; Ketterer, N; Koenecke, C; Null, O; Mohty, M; Cakana, A; Gorin, N; Null, W; Harousseau, J; Morris, C; Gahrton, G

doi:10.1200/JCO.2011.37.4918

Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. (2012). Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 30(20), 2475-2482 [10.1200/JCO.2011.37.4918].

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Garderet, L;IACOBELLI, SIMONA;Moreau, P;Dib, M;Lafon, I;Niederwieser, D;Masszi, T;Fontan, J;Michallet, M;Gratwohl, A;Milone, G;Doyen, C;Pegourie, B;Hajek, R;Casassus, P;Kolb, B;Chaleteix, C;Hertenstein, B;Onida, F;Ludwig, H;Ketterer, N;Koenecke, C;null, O;Mohty, M;Cakana, A;Gorin, N;null, W;Harousseau, J;Morris, C;Gahrton, G.

2012-01-01

Scheda breve

Scheda completa

Scheda completa (DC)

	Data di pubblicazione
	
				2012
			
	Status di pubblicazione
	
				Pubblicato
			
	DOI dell'articolo
	
				https://dx.doi.org/10.1200/JCO.2011.37.4918
			
	Rilevanza
	
				Rilevanza internazionale
			
	Tipo
	
				Articolo
			
	Referee
	
				Esperti anonimi
			
	Settore disciplinare dell'articolo (valido fino a 24/06/2024)
	
				Settore MED/01 - STATISTICA MEDICA
			
	Lingua del contenuto
	
				English
			
	Citazione
	
				Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. (2012). Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 30(20), 2475-2482 [10.1200/JCO.2011.37.4918].
			
	Tutti gli autori
	
						Garderet, L; Iacobelli, S; Moreau, P; Dib, M; Lafon, I; Niederwieser, D; Masszi, T; Fontan, J; Michallet, M; Gratwohl, A; Milone, G; Doyen, C; Pegouri...espandi
						
	Tipologia
	
				Articolo su rivista
			
	Appare nelle tipologie:
	
				01 - Articolo su rivista

File in questo prodotto:

File	Dimensione	Formato
Garderet_MMVAR_JCO 2012.pdf accesso aperto Licenza: Copyright dell'editore Dimensione 194.39 kB Formato Adobe PDF Visualizza/Apri	194.39 kB	Adobe PDF	Visualizza/Apri
Garderet_MMVAR_JCO editorial May 2012.pdf accesso aperto Licenza: Copyright dell'editore Dimensione 141.79 kB Formato Adobe PDF Visualizza/Apri	141.79 kB	Adobe PDF	Visualizza/Apri